Hepatic arterial infusion of paclitaxel for liver metastasis from gastric cancer.
Little is known about hepatic arterial infusion (HAI) of paclitaxel for hepatic malignancies. The authors administered paclitaxel via the HAI port in two patients with liver metastases from gastric cancer. Both patients were uneventfully treated without any serious complications, and its anti-tumor effect on 5-fluouracil resistant liver metastases was confirmed. However, the kinetics of venous paclitaxel concentration following HAI was similar to that after intravenous injection. Our findings did not support the advantage of paclitaxel HAI therapy, although HAI of this agent was well tolerated.